Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MeiraGTx
Biotech
J&J hands back failed gene therapy to MeiraGTx
Bota-vec failed a phase 3 trial after J&J shelled out $130 million upfront to fully acquire the gene therapy from MeiraGTx.
Darren Incorvaia
Apr 16, 2026 10:17am
Lilly bags eye-catching gene therapy in $475M deal
Nov 10, 2025 7:00am
Hologen AI commits $430M to MeiraGTx Parkinson's gene therapy
Mar 13, 2025 10:51am
MeiraGTx gene therapy allows 11 blind children to see
Feb 21, 2025 10:50am
MeiraGTx Parkinson's gene therapy boosts motor function in ph. 2
Oct 15, 2024 7:00am
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am